Seeking Alpha

More on Johnson & Johnson (JNJ) Q4: net profit excluding special items +7.9% to $3.4B; those...

More on Johnson & Johnson (JNJ) Q4: net profit excluding special items +7.9% to $3.4B; those items amount to $800M, and include "litigation accrual" and program costs associated with DePuy's recalled artificial hip. Acquisition of Synthes contributes 5.6% to sales growth. Domestic revenues +6.8%, international +8.9%. Shares -0.9%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector